Initial reports of KRASG12C inhibition showed that durable responses in mice were dependent on T cells, and a combination of KRASG12C inhibition and anti-PD1 led to improved survival in a subcutaneous tumor model of the genetically engineered G12C KRAS-mutant CT26 colon cancer cell line (8, 19). Here, KRAS is linked to neoplasm.